Reactivation of epigenetically silenced genes by DNA methyltransferase inhibitors: basic concepts and clinical...

Area of Science:

• Epigenetics and Cancer Biology
• Genomic Medicine

Background:

• Hypermethylation of tumor suppressor genes is a key epigenetic hallmark in human cancers.
• This process leads to gene silencing and loss-of-function mutations, contributing to tumorigenesis.
• Understanding these epigenetic alterations is crucial for developing targeted cancer therapies.

Purpose of the Study:

• To review systematic, genome-wide approaches for identifying epigenetically silenced genes in cancer.
• To explore the therapeutic potential of DNA methyltransferase inhibitors in cancer treatment.
• To discuss future directions for optimizing epigenetic cancer therapies.

Main Methods:

• Systematic literature review of genome-wide studies identifying epigenetically silenced loci.
• Analysis of clinical data on DNA methyltransferase inhibitors, particularly in leukemia therapy.
• Examination of drug-induced methylation changes as potential clinical endpoints.

Main Results:

• Genome-wide studies have identified numerous epigenetically silenced genes across various cancers.
• A common signature for epigenetic reactivation has not yet been consistently identified.
• DNA methyltransferase inhibitors have demonstrated significant clinical benefits, especially in leukemias.

Conclusions:

• Epigenetic silencing via hypermethylation is a critical mechanism in cancer development.
• Current DNA methyltransferase inhibitors show promise, with drug-induced methylation changes aiding treatment refinement.
• Development of novel, specific DNA methyltransferase inhibitors could broaden the application of epigenetic therapies in cancer treatment.